Literature DB >> 28480630

A Prospective Study of the Impact of Current Poverty, History of Poverty, and Exiting Poverty on Accumulation of Disease Damage in Systemic Lupus Erythematosus.

Edward Yelin1, Laura Trupin2, Jinoos Yazdany2.   

Abstract

OBJECTIVE: To estimate the effect of current poverty, number of years in poverty, and exiting poverty on disease damage accumulation in systemic lupus erythematosus (SLE).
METHODS: For this study, 783 patients with SLE were followed up from 2003 to 2015 through annual structured interviews. Respondents were categorized in each year by whether they had a household income of ≤125% of the US federal poverty level. Linear and logistic regression analyses were used to assess the impact of poverty in 2009, number of years in poverty between 2003 and 2009, and permanent exits from poverty as of 2009 on the extent of disease damage (according to the Brief Index of Lupus Damage [BILD] score) or accumulation of a clinically meaningful increase in disease damage (defined as a minimum 2-point increase in the BILD damage score) by 2015.
RESULTS: After adjustment for sociodemographic features, health care characteristics, and health behaviors, poverty in 2009 was associated with an increased level of accumulated disease damage in 2015 (mean difference in BILD damage score between poor and non-poor 0.62 points, 95% confidence interval [95% CI] 0.25-0.98) and increased odds of a clinically important increase in damage (odds ratio [OR] 1.67, 95% CI 0.98-2.85). Being poor in every year between 2003 and 2009 was associated with greater damage (mean change in BILD score 2.45, 95% CI 1.88-3.01) than being poor for one-half or more of those years (mean change in BILD score 1.45, 95% CI 0.97-1.93), for fewer than one-half of those years (mean change in BILD score 1.49, 95% CI 1.10-1.88), or for none of those years (mean change in BILD score 1.34, 95% CI 1.20-1.49). Those exiting poverty permanently had similar increases in disease damage (mean change in BILD score 1.30, 95% CI 0.90-1.69) as those who were never in poverty (mean change in BILD score 1.36, 95% CI 1.23-1.50) but much less damage than those who remained in poverty (mean change in BILD score 1.98, 95% CI 1.59-2.38).
CONCLUSION: The effects of current poverty, "dose" of poverty, and exiting poverty suggest that poverty plays a critical role in the accumulation of damage in patients with SLE.
© 2017, American College of Rheumatology.

Entities:  

Mesh:

Year:  2017        PMID: 28480630      PMCID: PMC5529220          DOI: 10.1002/art.40134

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  35 in total

Review 1.  Income inequality and mortality: importance to health of individual income, psychosocial environment, or material conditions.

Authors:  J W Lynch; G D Smith; G A Kaplan; J S House
Journal:  BMJ       Date:  2000-04-29

2.  Differences in CAHPS adult survey reports and ratings by race and ethnicity: an analysis of the National CAHPS benchmarking data 1.0.

Authors:  L S Morales; M N Elliott; R Weech-Maldonado; K L Spritzer; R D Hays
Journal:  Health Serv Res       Date:  2001-07       Impact factor: 3.402

3.  Lessons from LUMINA: a multiethnic US cohort.

Authors:  Graciela S Alarcón
Journal:  Lupus       Date:  2008-11       Impact factor: 2.911

4.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

5.  Interpersonal processes of care in diverse populations.

Authors:  A L Stewart; A Nápoles-Springer; E J Pérez-Stable
Journal:  Milbank Q       Date:  1999       Impact factor: 4.911

6.  Work dynamics among persons with systemic lupus erythematosus.

Authors:  Edward Yelin; Laura Trupin; Patricia Katz; Lindsey Criswell; Jinoos Yazdany; Joann Gillis; Peter Panopalis
Journal:  Arthritis Rheum       Date:  2007-02-15

7.  Depression, medication adherence, and service utilization in systemic lupus erythematosus.

Authors:  Laura J Julian; Edward Yelin; Jinoos Yazdany; Pantelis Panopalis; Laura Trupin; Lindsey A Criswell; Patricia Katz
Journal:  Arthritis Rheum       Date:  2009-02-15

8.  Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies.

Authors:  E W Karlson; L H Daltroy; C Rivest; R Ramsey-Goldman; E A Wright; A J Partridge; M H Liang; P R Fortin
Journal:  Lupus       Date:  2003       Impact factor: 2.911

9.  Validation of the systemic lupus erythematosus activity questionnaire in a large observational cohort.

Authors:  Jinoos Yazdany; Edward H Yelin; Pantelis Panopalis; Laura Trupin; Laura Julian; Patricia P Katz
Journal:  Arthritis Rheum       Date:  2008-01-15

10.  The role of neighborhood and individual socioeconomic status in outcomes of systemic lupus erythematosus.

Authors:  Laura Trupin; M Christine Tonner; Jinoos Yazdany; Laura J Julian; Lindsey A Criswell; Patricia P Katz; Edward Yelin
Journal:  J Rheumatol       Date:  2008-07-15       Impact factor: 4.666

View more
  17 in total

1.  Area-Level Predictors of Medication Nonadherence Among US Medicaid Beneficiaries With Lupus: A Multilevel Study.

Authors:  Candace H Feldman; Karen H Costenbader; Daniel H Solomon; S V Subramanian; Ichiro Kawachi
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-07       Impact factor: 4.794

2.  Poverty, Neighborhoods, Persistent Stress, and Systemic Lupus Erythematosus Outcomes: A Qualitative Study of the Patients' Perspective.

Authors:  Edward Yelin; Laura Trupin; Jared Bunde; Jinoos Yazdany
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-02-04       Impact factor: 4.794

3.  Racial Discrimination, Disease Activity, and Organ Damage: The Black Women's Experiences Living With Lupus (BeWELL) Study.

Authors:  David H Chae; Connor D Martz; Thomas E Fuller-Rowell; Erica C Spears; Tianqi Tenchi Gao Smith; Evelyn A Hunter; Cristina Drenkard; S Sam Lim
Journal:  Am J Epidemiol       Date:  2019-08-01       Impact factor: 4.897

4.  Race, Ethnicity, and Disparities in the Risk of End-Organ Lupus Manifestations Following a Systemic Lupus Erythematosus Diagnosis in a Multiethnic Cohort.

Authors:  Alfredo Aguirre; Zara Izadi; Laura Trupin; Kamil E Barbour; Kurt J Greenlund; Patti Katz; Cristina Lanata; Lindsey Criswell; Maria Dall'Era; Jinoos Yazdany
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-04-22       Impact factor: 5.178

5.  Association of Poverty Income Ratio with Physical Functioning in a Cohort of Patients with Systemic Lupus Erythematosus.

Authors:  Courtney Hoge; C Barrett Bowling; S Sam Lim; Cristina Drenkard; Laura C Plantinga
Journal:  J Rheumatol       Date:  2020-03-01       Impact factor: 4.666

6.  Sex Differences in Health Care Utilization, End-Stage Renal Disease, and Mortality Among Medicaid Beneficiaries With Incident Lupus Nephritis.

Authors:  Candace H Feldman; Anna Broder; Hongshu Guan; Jinoos Yazdany; Karen H Costenbader
Journal:  Arthritis Rheumatol       Date:  2018-02-06       Impact factor: 10.995

7.  Relationship Between Poverty and Mortality in Systemic Lupus Erythematosus.

Authors:  Edward Yelin; Jinoos Yazdany; Laura Trupin
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-04-24       Impact factor: 4.794

Review 8.  Updates to Adherence to Hypertension Medications.

Authors:  Paola C Roldan; Grant Y Ho; P Michael Ho
Journal:  Curr Hypertens Rep       Date:  2018-04-10       Impact factor: 5.369

9.  Pathways linking census tract typologies with subjective neighborhood disorder and depressive symptoms in the Black Women's Experiences Living with Lupus (BeWELL) Study.

Authors:  Connor D Martz; Evelyn A Hunter; Michael R Kramer; Yijie Wang; Kara Chung; Michael Brown; Cristina Drenkard; S Sam Lim; David H Chae
Journal:  Health Place       Date:  2021-06-09       Impact factor: 4.931

10.  Impact of Limited Health Literacy on Patient-Reported Outcomes in Systemic Lupus Erythematosus.

Authors:  Patricia Katz; Maria Dall'Era; Laura Trupin; Stephanie Rush; Louise B Murphy; Cristina Lanata; Lindsey A Criswell; Jinoos Yazdany
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-01       Impact factor: 5.178

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.